AYTU BIOPHARMA, INC
No enriched coverage for $AYTU in the last 7 days.
No SEC Form 4 filings for $AYTU in the last 30 days.
Aytu BioPharma (AYTU) delivered earnings and revenue surprises of -33.33% and +10.05%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Eton Pharmaceuticals (ETON) delivered earnings and revenue surprises of -153.85% and +9.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
AYTU, ALK and CNM have been added to the Zacks Rank #5 (Strong Sell) List on October 13, 2025.
